Cymserine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cymserine" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

7doi.org

2^nd place

2harvard.edu

18^th place

17^th place

1semanticscholar.org

11^th place

8^th place

1zenodo.org

621^st place

380^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. (2001). "A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase". Current Medical Research and Opinion. 17 (3): 159–65. doi:10.1185/0300799039117057. PMID 11900310. S2CID 21346884.
Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. (November 2005). "Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent". Proceedings of the National Academy of Sciences of the United States of America. 102 (47): 17213–8. Bibcode:2005PNAS..10217213G. doi:10.1073/pnas.0508575102. PMC 1288010. PMID 16275899.
Kamal MA, Al-Jafari AA, Yu QS, Greig NH (February 2006). "Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1760 (2): 200–6. doi:10.1016/j.bbagen.2005.10.003. PMID 16309845.
Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, Greig NH (September 2006). "Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine". Journal of Alzheimer's Disease. 10 (1): 43–51. doi:10.3233/jad-2006-10108. PMID 16988481.
Kamal MA, Klein P, Luo W, Li Y, Holloway HW, Tweedie D, Greig NH (May 2008). "Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine". Neurochemical Research. 33 (5): 745–53. doi:10.1007/s11064-007-9490-y. PMC 5201206. PMID 17985237.
Kamal MA, Qu X, Yu QS, Tweedie D, Holloway HW, Li Y, et al. (June 2008). "Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis". Journal of Neural Transmission. 115 (6): 889–98. doi:10.1007/s00702-008-0022-y. PMC 5193500. PMID 18235987.
Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. Bibcode:1990ToxAP.106...28S. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. (November 2005). "Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent". Proceedings of the National Academy of Sciences of the United States of America. 102 (47): 17213–8. Bibcode:2005PNAS..10217213G. doi:10.1073/pnas.0508575102. PMC 1288010. PMID 16275899.
Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. Bibcode:1990ToxAP.106...28S. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. (2001). "A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase". Current Medical Research and Opinion. 17 (3): 159–65. doi:10.1185/0300799039117057. PMID 11900310. S2CID 21346884.
Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. (November 2005). "Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent". Proceedings of the National Academy of Sciences of the United States of America. 102 (47): 17213–8. Bibcode:2005PNAS..10217213G. doi:10.1073/pnas.0508575102. PMC 1288010. PMID 16275899.
Kamal MA, Al-Jafari AA, Yu QS, Greig NH (February 2006). "Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1760 (2): 200–6. doi:10.1016/j.bbagen.2005.10.003. PMID 16309845.
Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, Greig NH (September 2006). "Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine". Journal of Alzheimer's Disease. 10 (1): 43–51. doi:10.3233/jad-2006-10108. PMID 16988481.
Kamal MA, Klein P, Luo W, Li Y, Holloway HW, Tweedie D, Greig NH (May 2008). "Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine". Neurochemical Research. 33 (5): 745–53. doi:10.1007/s11064-007-9490-y. PMC 5201206. PMID 17985237.
Kamal MA, Qu X, Yu QS, Tweedie D, Holloway HW, Li Y, et al. (June 2008). "Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis". Journal of Neural Transmission. 115 (6): 889–98. doi:10.1007/s00702-008-0022-y. PMC 5193500. PMID 18235987.
Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. Bibcode:1990ToxAP.106...28S. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.

ncbi.nlm.nih.gov

Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. (November 2005). "Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent". Proceedings of the National Academy of Sciences of the United States of America. 102 (47): 17213–8. Bibcode:2005PNAS..10217213G. doi:10.1073/pnas.0508575102. PMC 1288010. PMID 16275899.
Kamal MA, Klein P, Luo W, Li Y, Holloway HW, Tweedie D, Greig NH (May 2008). "Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine". Neurochemical Research. 33 (5): 745–53. doi:10.1007/s11064-007-9490-y. PMC 5201206. PMID 17985237.
Kamal MA, Qu X, Yu QS, Tweedie D, Holloway HW, Li Y, et al. (June 2008). "Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis". Journal of Neural Transmission. 115 (6): 889–98. doi:10.1007/s00702-008-0022-y. PMC 5193500. PMID 18235987.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. (2001). "A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase". Current Medical Research and Opinion. 17 (3): 159–65. doi:10.1185/0300799039117057. PMID 11900310. S2CID 21346884.

zenodo.org (Global: 621^st place; English: 380^th place)

Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. Bibcode:1990ToxAP.106...28S. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.

Cymserine (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

harvard.edu (Global: 18th place; English: 17th place)